newsfilter
← Latest News
PR Newswire·

Stealth BioTherapeutics Receives Refusal to File Letter from the FDA

BOSTON, Oct. 20, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (NASDAQ:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, to